观察活性维生素D、血管紧张素受体拮抗剂联合治疗IgA肾病的疗效及安全性

Efficacy and safety of active vitamin D(VD3) combined with angiotensin receptor antagonist in the treatment of IgA nephropathy

目的:探讨活性维生素D(VD_3)、血管紧张素受体拮抗剂联合治疗IgA肾病的疗效及安全性。方法:收治IgA肾病患者60例,随机分为对照组和观察组,每组各30例。对照组采用厄贝沙坦治疗,观察组采用厄贝沙坦联合VD_3治疗,比较两组治疗效果和安全性。结果:两组治疗后血压、血肌酐、血钙水平对比差异无统计学意义(P>0.05),观察组治疗后24 h尿蛋白量下降更为显著(P<0.05);观察组治疗后CD4^+、CD4^+/CD8^+水平改善效果明显更好(P<0.05)。结论:针对IgA肾病患者,选择VD_3、血管紧张素受体拮抗剂联合治疗,能减少尿蛋白量,改善治疗后免疫紊乱状态。

Objective:To explore the efficacy and safety of active vitamin D(VD3)combined with angiotensin receptor antagonist in the treatment of IgA nephropathy.Methods:60 patients with IgA nephropathy were selected,they were randomly divided into the control group and the observation group.The control group was treated with irbesartan and the observation group was treated with irbesartan combined with VD3.Results:There was no significant difference in blood pressure,serum creatinine and blood calcium level between the two groups after treatment(P>0.05).The decrease of urinary protein in the observation group after treatment for 24 hours was more significant(P<0.05).The improvement of CD4+and CD4+/CD8+levels in the observation group was significantly better after treatment(P<0.05).Conclusion:For IgA nephropathy patients,VD3 combined with angiotensin receptor antagonists can reduce urinary protein and improve the immune disorders after treatment.